SUMOylation inhibition enhances dexamethasone sensitivity in multiple myeloma

BACKGROUND: Multiple myeloma (MM) is an incurable plasma cell malignancy. Although Dexamethasone (Dex) is the most widely used therapeutic drug in MM treatment, patients develop Dex resistance leading to progressive disease, demanding an urgent need to investigate the mechanisms driving Dex resistan...

Descripción completa

Detalles Bibliográficos
Autores principales: Du, Li, Liu, Wei, Aldana-Masangkay, Grace, Pozhitkov, Alex, Pichiorri, Flavia, Chen, Yuan, Rosen, Steven T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8725350/
https://www.ncbi.nlm.nih.gov/pubmed/34983615
http://dx.doi.org/10.1186/s13046-021-02226-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8725350/
https://www.ncbi.nlm.nih.gov/pubmed/34983615
http://dx.doi.org/10.1186/s13046-021-02226-9

Ejemplares similares